Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical TrialMay 31, 2018
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical AchievementsMay 8, 2018
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial ResultsMarch 13, 2018
Press Release History
Website Developed by Alan Leff Associates, Inc.